XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 29, 2024
Jun. 30, 2023
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Protagenic Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2023 (the “Original Filing”) to correct an inadvertent error in the Original Filing. Exhibit 32.1 (Certification Pursuant To 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002) was inadvertently omitted from the filed version of the Original Filing. The Company is filing this Amendment solely for the purpose of including Exhibit 32.1.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-12555    
Entity Registrant Name Protagenic Therapeutics, Inc.\new    
Entity Central Index Key 0001022899    
Entity Tax Identification Number 06-1390025    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 149 Fifth Avenue    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10010    
City Area Code (212)    
Local Phone Number 994-8200    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 8,791,847
Entity Common Stock, Shares Outstanding   4,435,132  
Documents Incorporated by Reference None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] true    
Document Financial Statement Restatement Recovery Analysis [Flag] true    
Auditor Firm ID 206    
Auditor Name MaloneBailey, LLP    
Auditor Location Houston, Texas    
Common Stock [Member]      
Title of 12(b) Security Common Stock, par value $0.0001    
Trading Symbol PTIX    
Security Exchange Name NASDAQ    
Common Stock Purchase Warrant [Member]      
Title of 12(b) Security Common Stock Purchase Warrant    
Trading Symbol PTIXW    
Security Exchange Name NASDAQ